What we learned
Finding type 1 diabetes early
We heard the latest on research to detect and treat type 1 diabetes early. Scientists can now spot autoantibodies (early markers) before symptoms start. The ELSA study, funded by us and Breakthrough T1D, screens UK children for future risk and over 25,000 have joined so far. Dr Rachel Besser is launching a registry to track those who test positive, helping them access monitoring and trials. In the US, teplizumab is already approved. The session made clear we’re standing at the edge of a monumental change in type 1 diabetes management, and the UK is getting ready.
Dissecting diabetes stigma
New findings showed that people from Black African, Black Caribbean and South Asian communities often face stigma about diabetes. Many shared experiences of judgment in healthcare and at home, leading some to avoid appointments. These insights stress the need to act differently to support different communities. We’ll be using them to help shift attitutes and create new content to support families, friends and colleagues of people with diabetes.
Exercise matters for managing type 1 and 2
Physical activity is an important part of managing diabetes, and new research showed that timing and short bursts of movement can make a real difference. The CODEC study found that people with type 2 saw better blood sugar levels when they were active at a time that matched their natural rhythm, such as morning or evening. When the activity didn’t match this preference, there was no benefit. Research from Exeter showed that for people with type 1, 10-30 minutes of movement after meals helped reduce post-meal spikes. Together, these findings highlight simple, personalised ways to support blood sugar management.
Type 1 Diabetes Grand Challenge showcases pioneering research
The Type 1 Diabetes Grand Challenge took the spotlight, bringing together researchers and people with type 1 to share groundbreaking progress. From advancing beta cell therapies to enhancing immunotherapies that tackle type 1 at its roots, momentum is building. Global teams revealed next-gen insulins designed for faster, more precise action, easing daily diabetes management. The event also highlighted the importance of involving people living with type 1 in research. Experts shared strategies to ensure scientific breakthroughs translate into accessible treatments, underscoring a united effort to transform the future of type 1 care.
Culprits in type 2 beta cell damage
Dr Arden and her PhD student from the University of Newcastle are exploring ways to protect insulin-producing beta cells in type 2 diabetes. With our funding, they investigated toxic molecule buildup in beta cells, using human pancreas tissue. They found elevated NOX proteins in stressed beta cells and type 2 diabetes samples, linked to reduced insulin production. This suggests NOX proteins may drive beta cell failure. NOX-blocking drugs are already in development for diabetes complications, and this research hints they might also protect beta cells. Next, the team will test how changing NOX levels impacts these cells.
